NOTICE

with regard to the manufacturing license:
TICEBA possesses the required authorization by the competent authority for the manufacturing of tissue as source material of human origin for the manufacturing of pharmaceuticals in accordance with § 20 b and § 20 c of the German Medicines Act: Authorization for the treatment or processing, preservation, storage of tissue or tissue preparations.

Patents

TICEBA is exclusive licensee of the following patents:

Frank MH and Sayegh MH; Children's Hospital Boston and Brigham and Women's Hospital, Inc. "A gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof." US Patent 6,846,883. 25. January 2005.

Frank MH; Children's Hospital Boston "ABCB5 positive mesenchymal stem cells as immunmodulators." U.S. Provisional Patent Application No.: 60/809,407. 31. May 2006.

NEWS

		TICEBA receives SME eligibility of EMA. continue »

		TICEBA now on facebook. continue »

		next event: 29. - 31. May 2012, ECOPRAM - European Congress on Preventive, Regenerative and Anti-Aging Medicine, Istanbul (Turkey). Topic: "Autologous pluripotent mesenchymal stem cells from the skin". Booth: 12. continue »

INFORMATIONS

Request any information from us now.

request now

COUNSELLING

"We are glad to counsel you in person", Dr. Christoph Ganss:

+49 (0)6221.718 33 0

name:
email:

NOTICE

Patents

NEWS

NEWSLETTER

INFORMATIONS

COUNSELLING